Market revenue in 2024 | USD 9,552.9 million |
Market revenue in 2030 | USD 9,124.8 million |
Growth rate | -1.2% (CAGR from 2025 to 2030) |
Largest segment | Eylea |
Fastest growing segment | Vabysmo |
Historical data covered | 2018 - 2023 |
Base year for estimation | 2024 |
Forecast period covered | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Eylea, Lucentis, Beovu, Vabysmo |
Key market players worldwide | Roche Holding AG ADR, Biogen Inc, Pfizer Inc, Amgen Inc, Bausch Health Companies Inc, Viatris Inc, Coherus BioSciences Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to anti-vascular endothelial growth factor therapeutics market will help companies and investors design strategic landscapes.
Eylea was the largest segment with a revenue share of 59.47% in 2024. Horizon Databook has segmented the North America anti-vascular endothelial growth factor therapeutics market based on eylea, lucentis, beovu, vabysmo covering the revenue growth of each sub-segment from 2018 to 2030.
Growth of North America’s anti-VEGF therapeutics market can be attributed to various factors, such as high burden of disease and increase in favorable government initiatives. Funding for research is high in the region. Moreover, increasing product launches and demand for medicines are expected to positively impact growth of the regional market.
In addition, technological advancements in medications may fuel market growth. For instance, in May 2020, F. Hoffmann-La Roche Ltd. announced the topline phase 3 clinical trial results for formulation advancement of ranibizumab with Port Delivery System.
An article suggests that direct healthcare costs of visual impairment due to AMD accounted for USD 98 billion in the WHO subregion AMR-A, which covers the U.S., Canada, and Cuba. Presence of leading products, such as Avastin, Eylea, and Lucentis, among others, is expected to improve availability of treatment in the region.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America anti-vascular endothelial growth factor therapeutics market , including forecasts for subscribers. This continent databook contains high-level insights into North America anti-vascular endothelial growth factor therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account